Michael D. Chan
YOU?
Author Swipe
View article: INNV-51. Rapid response to encorafenib and binimetinib (Enc/Bini) in a patient with recurrent ganglioglioma with leptomeningeal spread
INNV-51. Rapid response to encorafenib and binimetinib (Enc/Bini) in a patient with recurrent ganglioglioma with leptomeningeal spread Open
Our patient was a 20-year-old female when diagnosed with a left parietal WHO Grade III anaplastic ganglioglioma (AGG) with BRAFV600E mutation, APC rearrangement exon 16 and CDKN2A/B loss per next generation sequencing after presenting with…
View article: From sparks to action: the role of political influencers for young adults’ political efficacy and political participation in Austria, Hong Kong, Indonesia, and Serbia
From sparks to action: the role of political influencers for young adults’ political efficacy and political participation in Austria, Hong Kong, Indonesia, and Serbia Open
Two types of social media influencers play an important role in political communication: those who hardly post political content in addition to their regular content (i.e., social media influencers; SMIs) and those who specifically focus o…
View article: Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields
Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields Open
This is the first report showing in vitro antitumor activity, disruption of the mitotic spindle, activation of the Mitotic Roles of Polo-like kinase pathway in GB. This is also the first report showing feasibility and clinical activ…
View article: Genomic Signature to Predict Neurologic Death in Non-Small Cell Lung Cancer Patients
Genomic Signature to Predict Neurologic Death in Non-Small Cell Lung Cancer Patients Open
View article: MRI-Based Radiomics Ensemble Model for Predicting Radiation Necrosis in Brain Metastasis Patients Treated with Stereotactic Radiosurgery and Immunotherapy
MRI-Based Radiomics Ensemble Model for Predicting Radiation Necrosis in Brain Metastasis Patients Treated with Stereotactic Radiosurgery and Immunotherapy Open
Background: Radiation therapy is a primary and cornerstone treatment modality for brain metastasis. However, it can result in complications like necrosis, which may lead to significant neurological deficits. This study aims to develop and …
View article: Genomic Signature for Initial Brain Metastasis Velocity (iBMV) in Non-Small-Cell Lung Cancer Patients: The Elusive Biomarker to Predict the Development of Brain Metastases?
Genomic Signature for Initial Brain Metastasis Velocity (iBMV) in Non-Small-Cell Lung Cancer Patients: The Elusive Biomarker to Predict the Development of Brain Metastases? Open
Background/Objectives: No prior studies have attempted to identify a biomarker for initial brain metastasis velocity (iBMV), with limited studies attempting to correlate genomic data with the development of brain metastases. Methods: Patie…
View article: Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation
Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation Open
Glioblastoma (GBM) remains the most aggressive primary brain tumor in adults, with no effective treatments. While cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) show clinical promise in some cancers, they have not significantly improved…
View article: Extrapulmonary Small Cell Carcinoma: A Single-Institution Review of Brain Metastases, Treatment Paradigms, and Patient Outcomes
Extrapulmonary Small Cell Carcinoma: A Single-Institution Review of Brain Metastases, Treatment Paradigms, and Patient Outcomes Open
View article: Corrigendum to—“Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF”—[eBiomedicine, 44 (2019) 194–208]
Corrigendum to—“Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF”—[eBiomedicine, 44 (2019) 194–208] Open
View article: Fractionated Radiotherapy With Stereotactic Radiosurgery Boost Controls Gross Disease in Grade 2 Meningioma
Fractionated Radiotherapy With Stereotactic Radiosurgery Boost Controls Gross Disease in Grade 2 Meningioma Open
We found 100% in-field local control at 3 years from an SRS boost to fractionated RT targeting gross disease with an acceptable toxicity profile, suggesting this may be an effective and improved adjuvant treatment strategy in patients with…
View article: Supplementary Table 1-16 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary Table 1-16 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Supplementary Table 1-16
View article: Supplementary figure 4 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary figure 4 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Supplementary figure 4
View article: Supplementary figure 2 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary figure 2 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Supplementary figure 2
View article: Supplementary figure 3 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary figure 3 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Supplementary figure 3
View article: Supplementary figure 6 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary figure 6 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Supplementary figure 6
View article: Supplementary figure 5 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary figure 5 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Supplementary figure 5
View article: Supplementary figure 1 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Supplementary figure 1 from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Supplementary figure 1
View article: Data from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Data from Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Treatment of non–small cell lung cancer (NSCLC) has drastically changed in recent years owing to the robust anticancer effects of immune checkpoint inhibitors (ICI). However, only 20% of the patients with NSCLC benefit from ICIs, highlight…
View article: Correction: Regua et al. TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. Cancers 2021, 13, 2340
Correction: Regua et al. TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. Cancers 2021, 13, 2340 Open
In the original publication [...]
View article: “If You’re Talking, I Think You’re Muted”: Follow-up Analysis of Weekly Peer Review Discussion and Plan Changes After Transitioning From Virtual to In-Person Format
“If You’re Talking, I Think You’re Muted”: Follow-up Analysis of Weekly Peer Review Discussion and Plan Changes After Transitioning From Virtual to In-Person Format Open
View article: Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases
Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases Open
Purpose/objective(s) Biomarkers for extracranial oligometastatic disease remain elusive and few studies have attempted to correlate genomic data to the presence of true oligometastatic disease. Methods Patients with non-small cell lung can…
View article: Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer
Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non–Small Cell Lung Cancer Open
Treatment of non–small cell lung cancer (NSCLC) has drastically changed in recent years owing to the robust anticancer effects of immune checkpoint inhibitors (ICI). However, only 20% of the patients with NSCLC benefit from ICIs, highlight…
View article: Exposed Phosphatidylserine as a Biomarker for Clear Identification of Breast Cancer Brain Metastases in Mouse Models
Exposed Phosphatidylserine as a Biomarker for Clear Identification of Breast Cancer Brain Metastases in Mouse Models Open
Brain metastasis is the most common intracranial malignancy in adults. The prognosis is extremely poor, partly because most patients have more than one brain lesion, and the currently available therapies are nonspecific or inaccessible to …
View article: Targeting Exposed Phosphatidylserine Enables the Clear Demarcation of Brain Metastases in Mouse Models
Targeting Exposed Phosphatidylserine Enables the Clear Demarcation of Brain Metastases in Mouse Models Open
Brain metastasis is the most common intracranial malignancy in adults. The prognosis is extremely poor, partly because most patients have more than one brain lesion, and the currently available therapies are nonspecific or inaccessible to …
View article: Treatment Options for Brain Metastases
Treatment Options for Brain Metastases Open
Opinion Statement Therapies for brain metastasis continue to evolve as the life expectancies for patients have continued to prolong. Novel advances include the use of improved technology for radiation delivery, surgical guidance, and respo…
View article: Radiogenomics-Based Risk Prediction of Glioblastoma Multiforme with Clinical Relevance
Radiogenomics-Based Risk Prediction of Glioblastoma Multiforme with Clinical Relevance Open
Glioblastoma multiforme (GBM)is the most common and aggressive primary brain tumor. Although temozolomide (TMZ)-based radiochemotherapy improves overall GBM patients’ survival, it also increases the frequency of false positive post-treatme…
View article: Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach
Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based Approach Open
The quality of radiation therapy (RT) treatment plans directly affects the outcomes of clinical trials. KBP solutions have been utilized in RT plan quality assurance (QA). In this study, we evaluated the quality of RT plans for brain and h…
View article: The role of radiotherapy in immunotherapy strategies in the central nervous system
The role of radiotherapy in immunotherapy strategies in the central nervous system Open
The clinical efficacy and relative tolerability of adverse effects of immune checkpoint immunotherapy have led to its increasingly routine use in the management of multiple advanced solid malignancies. Radiation therapy (RT) is well-known …
View article: Use of comprehensive genomic profiling for biomarker discovery for the management of non-small cell lung cancer brain metastases
Use of comprehensive genomic profiling for biomarker discovery for the management of non-small cell lung cancer brain metastases Open
Background Clinical biomarkers for brain metastases remain elusive. Increased availability of genomic profiling has brought discovery of these biomarkers to the forefront of research interests. Method In this single institution retrospecti…
View article: INNV-32. RELIABILITY OF SERIAL NEUROPATHOLOGICAL ASSESSMENT TO DIFFERENTIATE TUMOR PROGRESSION FROM PSEUDO-PROGRESSION IN GLIOMA
INNV-32. RELIABILITY OF SERIAL NEUROPATHOLOGICAL ASSESSMENT TO DIFFERENTIATE TUMOR PROGRESSION FROM PSEUDO-PROGRESSION IN GLIOMA Open
Histopathology is the gold standard for distinguishing tumor recurrence from treatment-induced necrosis but differentiating pseudoprogression from true recurrence is challenging in tumors with ambiguous morphological features. Prior resear…